Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge

Future Cardiol. 2017 May;13(3):247-257. doi: 10.2217/fca-2017-0002. Epub 2017 Jun 1.

Abstract

Acute coronary syndrome (ACS) coinciding with active malignancy presents a unique clinical challenge given intersecting pathophysiology and treatment-related effects. There is little established clinical guidance on management strategies, rendering most treatment approaches anecdotal. We present a case highlighting the complexity of managing a patient being treated for malignancy who concurrently suffers from ACS. We then review the literature on co-management of ACS and malignancy, including reports of specific cancer therapies associated with ACS, unique features of clinical presentation and optimal use of dual antiplatelet therapy to minimize risks of bleeding and thrombosis. We also describe gaps in current literature, challenges in systematically studying the clinical intersection of these disease processes and propose alternative methodologies for further research.

Keywords: acute coronary syndrome; cancer; cardio-oncology; chemotherapy; ischemic heart disease.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acute Coronary Syndrome
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / therapy*
  • Hemorrhage / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / etiology
  • Myocardial Ischemia / chemically induced
  • Myocardial Ischemia / therapy*
  • Stents*
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / etiology

Substances

  • Antineoplastic Agents